Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To define the proportion of patients with PFS at 12 weeks with the combination of R1507 and erlotinib or a corresponding placebo and erlotinib in patients with advanced Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) who have failed at least one standard chemotherapy regimen.
Inclusion criteria
- Advanced (Stage IIIb/IV) Non Small Cell Lung Cancer patients who have failed at least one but no more than two standard chemotherapy regimens